ZC3H12A

Across TCGA pan-cancer cohorts, ZC3H12A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZC3H12A data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher ZC3H12A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZC3H12A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, LIHC, and SKCM are the cancer types where ZC3H12A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.112	0.484	.015	12	view →
LIHC	OS	Median	II,III,IV	0.011	0.716	<.001	12	view →
SKCM	OS	Median	IV	0.415	0.861	.014	9	view →
SARC	OS	Median	All	0.127	0.860	<.001	6	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →
UCEC	OS	Median	All	0.958	0.651	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZC3H12A–PAAD (DFS)

Open the PAAD breakdown →